Efficacy of single-agent lenalidomide in patients with JAK2 (V617F) mutated refractory anemia with ring sideroblasts and thrombocytosis

Blood

Volumn 116, Issue 2, 2010, Pages 180-182

  Huls, Gerwin ^a   Mulder, André B ^a   Rosati, Stefano ^a   Van De Loosdrecht, Arjan A ^b   Vellenga, Edo ^a   De Wolf, Joost T M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; HEMOGLOBIN; HYDROXYUREA; JANUS KINASE 2; LENALIDOMIDE; PREDNISONE; PYRIDOXINE; STEROID; ANABOLIC AGENT; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; THALIDOMIDE; VITAMIN B COMPLEX;

AGED; ARTICLE; AUTOIMMUNE HEMOLYTIC ANEMIA; BLOOD TRANSFUSION; BONE MARROW BIOPSY; CASE REPORT; CHRONIC DISEASE; CYTOREDUCTIVE SURGERY; DRUG ACTIVITY; DRUG EFFICACY; FEMALE; GENE MUTATION; HEMOGLOBIN BLOOD LEVEL; HUMAN; LUNG EMBOLISM; MEAN CORPUSCULAR VOLUME; MEGAKARYOCYTE; OUTCOME ASSESSMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUANTITATIVE ANALYSIS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REMISSION; THROMBOCYTOSIS; TREATMENT DURATION; TREATMENT FAILURE; GENETICS; MALE; MIDDLE AGED; MUTATION; REFRACTORY ANEMIA; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIDEROBLASTIC ANEMIA;

AGED, 80 AND OVER; ANABOLIC AGENTS; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; ANTINEOPLASTIC AGENTS; ERYTHROPOIETIN; HUMANS; HYPERTENSION, PULMONARY; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; PULMONARY EMBOLISM; PYRIDOXINE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; THALIDOMIDE; THROMBOCYTOSIS; VITAMIN B COMPLEX;

EID: 77955481915     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-01-263087     Document Type: Article

References (21)

1. Vardiman JW, Bennet JM, Bain BJ, Bauman I, Thiele J, Orazi A. Myelodysplastic/myeloproliferative neoplasms, unclassifiable. In: Swerdlow SH, Camp E, Harris NL, et al, eds. Who Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC; 2008:85-86.
2. Remacha AF, Nomdedéu JF, Puget G, et al. Occurrence of the JAK2 V617F mutation in the WHO provisional entity: myelodysplastic/myeloproliferative disease, unclassifiable-refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2006;91(5):719-720. (Pubitemid 43799483)
3. Szpurka H, Tiu R, Murugesan G, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T), another myeloproliferative condition characterized by JAK2 V617F mutation. Blood. 2006;108(7):2173-2181.
4. Wang SA, Hasserjian RP, Loew JM, et al. Refractory anemia with ringed sideroblasts associated with marked thrombocytosis harbors JAK2 mutation and shows overlapping myeloproliferative and myelodysplastic features. Leukemia. 2006;20(9):1641-1644.
5. Boissinot M, Garand R, Hamidou M, Hermouet S. The JAK2-V617F mutation and essential thrombocythemia features in a subset of patients with refractory anemia with ring sideroblasts (RARS). Blood. 2006;108(5):1781-1782. (Pubitemid 44316158)
6. Renneville A, Quesnel B, Charpentier A, et al. High occurrence of JAK2 V617 mutation in refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Leukemia. 2006;20(11):2067-2070.
7. Ceesay MM, Lea NC, Ingram W, et al. The JAK2 V617F mutation is rare in RARS but common in RARS-T. Leukemia. 2006;20(11):2060-2061.
8. 9/L) and ringed sideroblasts more than 15% considered as MDS/MPD, unclassifiable. Blood. 2007;109(3):1334-1335.
9. Schmitt-Graeff AH, Teo SS, Olschewski M, et al. JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Haematologica. 2008;93(1):34-40.
10. Schnittger S, Bacher U, Haferlach C, et al. Detection of an MPLW515 mutation in a case with features of both essential thrombocythemia and refractory anemia with ringed sideroblasts and thrombocytosis. Leukemia. 2008;22(2):453-455. (Pubitemid 351265131)
11. Shaw GR. Ringed sideroblasts with thrombocytosis: an uncommon mixed myelodysplastic/myeloproliferative disease of older adults. Br J Haematol. 2005;131(2):180-184.
12. Malcovati L, Della Porta MG, Pietra D, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(7):3538-3545.
13. Wardrop D, Steensma DP. Is refractory anaemia with ring sideroblasts and thrombocytosis (RARS-T) a necessary or useful diagnostic category? Br J Haematol. 2009;144(6):809-817.
14. Hellström-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program. 2008;52-59.
15. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352(6):549-557.
16. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355(14):1456-1465.
17. Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood. 2008;111(1):86-93.
18. Quintás-Cardama A, Kantarjian HM, Manshouri T, et al. Lenalidomide plus prednisone results in durable clinical, histopathologic, and molecular responses in patients with myelofibrosis. J Clin Oncol. 2009;27(28):4760-4766.
19. Quentmeier H, MacLeod RA, Zaborski M, Drexler HG. JAK2V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders. Leukemia. 2006;20(3):471-476. (Pubitemid 43291746)
20. Sun WL, Köck L, Walder A, et al. Successful treatment of MDS with lenalidomide, complicated by transient autoimmune hemolysis. Ann Hematol. 2010;89(3):327-329.
21. Flach J, Dicker F, Schnittger S, Kohlmann A, Haferlach T, Haferlach C. Mutations of TET2 or JAK2 but not CBL are detectable in a high portion of patients with refractory anemia with ring sideroblasts and thrombocytosis. Haematologica. 2010;95(3):518-519.